EchoNous is highlighting the results of a study suggesting the company's Kosmos ultrasound system improves cardiac evaluations in chemotherapy patients.
The study, published in the European Heart Journal, found that the ultrasound system allowed ultrasound practitioners of all experience levels to accurately and quickly assess left ventricular ejection fraction (LVEF), an indicator of heart health and a measure to monitor in patients undergoing chemotherapy treatment. The study involved 115 patients and had oncology staff perform heart scans using the Kosmos system. The findings showed that the nonultrasound experts achieved diagnostic accuracies between 89% to 94%.
Kosmos is equipped with AI algorithms Trio and Kosmos Auto EF and guides users through the scanning process. The system also produces echocardiographic images at the point of care.
EchoNous will showcase the Kosmos system at the 2024 American Society of Clinical Oncology (ASCO) annual meeting from May 31 to June 4.
